High kinase activity BRAF complexes phosphorylate MAP2Ks

Stable Identifier
R-HSA-6802911
Type
Reaction [transition]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Highly active BRAF mutants such as V600E are constitutively active and phosphorylate MAP2Ks in a RAS- and dimer interface-independent manner (Davies et al, 2002; Wan et al, 2004; Garnett et al, 2005; Roring et al, 2012; Poulikakos et al, 2010; reviewed in Lavoie and Therrien, 2015).
Literature References
PubMed ID Title Journal Year
25907612 Regulation of RAF protein kinases in ERK signalling

Lavoie, H, Therrien, M

Nat. Rev. Mol. Cell Biol. 2015
22510884 Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

Fiala, GJ, Herr, R, Röring, M, Heilmann, K, Schamel, WW, Saunders, DN, Halbach, S, Capper, D, Brummer, T, Braun, S, von Deimling, A, Eisenhardt, AE

EMBO J. 2012
12068308 Mutations of the BRAF gene in human cancer

Maitland, N, Jayatilake, H, Futreal, PA, Yuen, ST, Marshall, CJ, Menzies, A, Parker, A, Chenevix-Trench, G, Leung, SY, Garnett, MJ, Davis, N, Shipley, J, Cooper, C, Darrow, TL, Marais, R, Paterson, H, Palmieri, G, Floyd, Y, Bottomley, W, Bigner, DD, Bignell, GR, Stevens, C, Cossu, A, Hall, S, Ho, JW, Wilson, R, Mould, C, Gusterson, BA, Watt, S, Cox, C, Riggins, GJ, Flanagan, A, Gray, K, Wooster, R, Hooper, S, Teague, J, Ewing, R, Edkins, S, Seigler, HF, Hargrave, D, Hawes, R, Kosmidou, V, Nicholson, A, Stephens, P, Weber, BL, Hughes, J, Davies, H, Woffendin, H, Stratton, MR, Clegg, S, Dicks, E, Pritchard-Jones, K

Nature 2002
16364920 Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

Garnett, MJ, Barford, D, Paterson, H, Rana, S, Marais, R

Mol. Cell 2005
15035987 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Niculescu-Duvaz, D, Lee, S, Marais, R, Marshall, CJ, Barford, D, Jones, CM, Good, VM, Springer, CJ, Wan, PT, Garnett, MJ, Roe, SM

Cell 2004
20179705 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Shokat, KM, Zhang, C, Bollag, G, Rosen, N, Poulikakos, PI

Nature 2010
Participants
Participates
Catalyst Activity

protein serine/threonine kinase activity of high kinase activity BRAF mutants:scaffold:MAP2K:MAPK complex [cytosol]

Normal reaction
Functional status

Gain of function of high kinase activity BRAF mutants:scaffold:MAP2K:MAPK complex [cytosol]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!